尔康制药：控股股东拟减持不超2.04%股份

Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Shuai Fangwen, plans to reduce his stake in the company by up to 42 million shares, representing 2.04% of the total share capital, within a three-month period starting from October 29, 2025, to January 28, 2026 [1] Summary by Relevant Categories Shareholder Actions - Shuai Fangwen intends to reduce his holdings through centralized bidding or block trading methods [1] Share Capital Impact - The planned reduction amounts to a maximum of 42 million shares, which is equivalent to 2.04% of the company's total share capital [1]